Member Info for Jurado

Tremendous piece about Greggs and British society here - proud to be long-term holder. https://www.theguardian.com/lifeandstyle/2019/jan/07/greggs-vegan-sausage-roll-brexit-britain-culture-wars?fbclid=IwAR3Sk8yrVya1VapsfdEhsXZuYnWLmFyJrlwN_NIQttzDVjskjv4ZzHVA6Z4

Fourth quarter/Christmas trading figures tomorrow. The fact that we're up £1 already this month makes me think the market is pricing in some fairly splendid numbers. So maybe we should be prepared for a fall if they are not quite as good - but whether they are very good or not quite as good as some had thought, I'm very happy with the way things have gone over the years here and expect a continuation of the nice divis for some time to come.

"Hahahahahahaha. I knew it. BBC right-of-centre = palatable, non-tribal leftism." Prime gammon - confronted with a fact he doesn't like, he'll just move the goal posts. And allegiance to a croaky old concept such as IQ shows this fellow's irrelevance even more. Anyway welcome Ms Shaw - hope you enjoy the journey.

I can't quite believe you are moaning that 11 months after launching a domestic machine using completely new technology at a trade show, we have not gained floor space at Curry's. As for your anecdote about your 'local suppliers' - did you really invest here thinking that brand awareness in Belo Horizonte, Tamworth or Dortmund would rival Zanussi by the end of 2018? There's plenty of challenges facing Xeros, as having to fundraise at 10p indicates, but give them a bloody chance.

I'd hope that the markets would place as much credence in what he says as the rest of the world, but this is a worrying drop now. I kind of hoped that this being predominantly a US business right now, we might be a bit insulated from the fears around Brexit omnishambles.

Maybe a obvious question and maybe there's an obvious answer, but why would they fundraise at 10p? Do they really feel the institutions wouldn't have been interested at 28? 25? 20? 15? I'm reluctant to believe this is simply selling it to mates at rock bottom, but maybe I'm just naïve.

Course we're interested. It's just when you are trading at around one sixth the price of this time last year, it's hard to get over-excited about small-but-welcome announcements. I'm still confident the business is a good one and in the medium term am excited about making money. But there's still a way to go before we see major movement. Happy to be put right if anyone thinks this is actually a very significant step on the road to mass licensing.

Reasonably sustained rise of around 15 per cent over four days - anyone got a scooby? Is it just macro stuff?

A £50m investment from Amgen into Oxford Nanopore - that sounds like one considerable vote of confidence. It's cheered me up after the Diurnal disappointment and the continuing XSG doldrums. That's the thing with investing in this company - there's always so many ups and downs coming at us as portfolio companies grow or flounder.

I really wouldn't worry (unless you need to sell today at a loss). These things will happen and I'd today's fall is just linked to macroeconomic jitters - virtually everyone is down today and with us just announcing we're making a quite big capital investment over the next year we're probably seen as a risk. Sentiment can and will change very quickly though. This is most definitely a share to stay in for at least three years but if you can't take the ups and downs I'd get out once you show a profit.

Great piece from the BBC today - https://www.bbc.co.uk/news/business-45711230 - good info on the huge savings being made by our customers in South Africa.

Has just tripled his holding. He's still not got much, but can't be a bad sign.

Nicholls was interviewed on Proactive Investor a couple of days ago reiterating very clearly that last year's fundraise would bring us to late this year and another fundraise would follow "on the back of hard evidence" - which has now started to come through. Assuming we maintain most of today's rise, the fundraise should follow shortly. All good for LTHs.

It might. It might not. But thanks for your helpful contribution.

In other news "Xeros Technology Group plc announces the supply of 32 near-waterless washing machines to Encom Trading LLC, a wholly owned subsidiary of Electro RAK, a leading UAE-based infrastructure services company and the appointed partner in the UAE to Hydrofinity, Xeros' cleaning technologies brand.Electro RAK intends to install machines in premium hotels in the UAE. The first shipment will be made to Dubai during September."

Good news after the recent Cape Town order. These may be fairly small numbers but they show people are looking for solutions in the most water-stressed parts of the world. The more examples we can point to, the greater the likelihood of those numbers starting to grow significantly.

If I read it all correctly, the Hardman report suggested Dermapure sales growth of 37%, we got 73%. They said 50% growth at GBMV, we got 70%. EBITDA loss would increase to 4.9m, it shrank to £3.5m. Overall sales growth predicted at 33%, turned out to be 61%. So it seems we did indeed do significantly better than that report suggested. Not sure whether the market expected that - currently up around 6 per cent - nice, but not spectacular. Let's hope it's the start of a steady climb.

No activity here for five months, but if anyone is looking for further info it's worth looking at the article in the Sunday Times this Sunday, 26 August. https://www.thetimes.co.uk/article/has-the-world-of-biotech-investing-become-just-a-little-too-cosy-kg79qgprm - It's a generally sceptical piece that reflects on our reliance on Oxford Nanopore and the difficult stage that business is at as it looks at a Hong Kong listing. Also there's plenty of discussion over the investor base and the role of Woodford and Invesco. I think the case remains for a punt here - maybe not a big one, but a punt nonetheless and now is as good a time as any with the sp low and push coming to shove for our biggest asset.

Welcome news but we've always been confident that we were better than vancomycin. The issue has been whether big pharma was willing to take on such products. I can't see a sustained rise much above 50p just yet until science and route to market are clearer. Also, I know it's pointless, but wouldn't it have been lovely to see this happening if we were still in the game for DMD?

If the figures are better than Hardman suggest, then it seems to suggest a game of double bluff on the market by TRX and surely the IIs are cute to that. Whatever, I hope Nomlungu is right - the science and the business strategy here seem convincing to me and I'm reasonably confident that will, erm, trump the problems cited.

So it seems that, effectively, we've got the results today not next month. I don't see there's reason to doubt Hardman's figures and their "good progress, but still two/three years until any profits" verdict probably explains the little dip this week. I'm not saying this is a " tuck under the mattress and forget about share" - I still have a feeling there could be events over the coming months that make it worth checking in regularly - but any growth in sp is likely to be pretty slow I'd guess. A very good entry price though for any patient investors.

Down 9 per cent on three trades worth a total of £1700. Not going to worry about that until I hear something worth worrying about.